The results of the Precision-T Phase 3 study of investigational allogeneic T-cell immunotherapy, Orca-T, were published in the journal Blood.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

A specific graft-versus-host disease prophylaxis regimen may expand allogeneic hematopoietic stem cell transplant access to ...

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

A "hybrid" immune system approach may prevent or cure Type 1 diabetes (T1D) by combining blood stem cell and islet cell transplants. The method uses a nonmyeloablative conditioning regimen to prevent ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

Patient enrolment completed in Cynata Therapeutics’ Phase II clinical trial of CYP-001 in high risk acute graft versus host ...

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...